ITEM 7.01 REGULATION FD DISCLOSURE

On January 12, 2020, Zymeworks Inc. issued a press release announcing the initiation of a Phase 2 trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. On January 13, 2020, this press release was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com. A copy of this press release is attached as exhibit 99.1 hereto.

On January 13, 2020, Zymeworks Inc. issued a press release highlighting its key accomplishments in 2019, providing updated corporate priorities, and announcing multiple clinical program advances for its lead candidates, ZW25 and ZW49. On January 13, 2020, this press release was filed with the Canadian securities regulatory authorities in Canada on SEDAR at www.sedar.com. A copy of this press release is attached as exhibit 99.2 hereto.

The information provided under this Item (including exhibits 99.1 and 99.2, attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS




(d) Exhibits



             Exhibit No.                  Description

             99.1            Press Release dated January 12, 2020.

             99.2            Press Release dated January 13, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses